SYBD.OB

[setravis]

ANNOUNCES PLANS TO FINALIZE PH IIB TRIAL PROTOCOL: Synthetic Blood International,
Inc. (SYBD) announced its plan to finalize a Phase IIb clinical trial protocol with Oxycyte(TM) for
the treatment of traumatic brain injury (TBI) at its Scientific Advisory Board (SAB) meeting scheduled
for Thursday, December 13, 2007. Oxycyte is Synthetic Blood's proprietary perfluorocarbon
(PFC) therapeutic oxygen carrier and blood substitute. The SAB plans to develop a strategy for
initiating supportive preclinical studies to explore the basic science of Oxycyte's oxygen delivery
capabilities for the treatment of damaged brain tissue, and the effects of higher Oxycyte doses
than have been used in previous studies, as well as the potential effects of administering second
doses of Oxycyte.

[setravis]

Profile: 


Synthetic Blood International Inc.
3189 Airway Avenue
Building C
Costa Mesa, CA 92626
United States - Map
Phone: 714-427-6363
Fax: 714-427-6361
Web Site: http://www.sybd.com

DETAILS   
Index Membership: N/A
Sector: Services
Industry: Research Services
Full Time Employees: 6


BUSINESS SUMMARY   
Synthetic Blood International, Inc. develops biotechnology products. It focuses on developing Oxycyte, a product alternative to transfused blood for use in surgical and similar medical situations. Oxycyte blood substitute product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously. The properties of perfluorocarbon enable the product to gather oxygen from the lungs and transport the oxygen through the body releasing it along the way. Oxycyte is intended as a transfusion substitute for blood transfusion that ordinarily would be applied in cases of trauma, surgery (emergency and elective), unexpected blood loss, and other general medical applications. In addition, the company also develops Fluorovent, an oxygen exchange fluid for facilitating the treatment of lung conditions; and a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. In addition, it holds patents pertaining to the use and application of perfluorocarbons as gas transport agents in blood substitutes and liquid ventilation. The company was founded in 1967 and is based in Costa Mesa, California.

[kslifka]

SYBD.ob may be setting up for a break-out.

News from today is helping it along.


Synthetic Blood Announces Oxycyte Development Strategy
Monday December 17, 10:41 am ET

COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB: SYBD - News) today announced its near-term development strategy for Oxycyte™. The Company finalized its Phase IIb Oxycyte clinical trial protocol for the treatment of traumatic brain injury (TBI), and plans to initiate three pre-clinical animal studies in sickle cell disease, spinal cord injury and stroke in the first half of 2008. Oxycyte is the Company's proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.

ADVERTISEMENT
These Oxycyte development initiatives were determined at the Company's Scientific Advisory Board (SAB) meeting conducted last week. Synthetic Blood also announced its intention to invite six to eight physicians to join the SAB in a move to broaden its specialties. The SAB candidates are expected to be primarily located at medical centers that may be involved with Oxycyte trials.

"We have taken a major step toward FDA submission of a Phase IIb protocol in TBI," said Robert Larsen, Interim President and CEO of Synthetic Blood. "Further, favorable data from our Phase IIa pilot clinical study in TBI demonstrated Oxycyte's ability to provide oxygen transport to tissues immediately after injury. Based on these and other study data, we believe that Oxycyte could significantly reduce permanent damage and improve recovery outcomes in additional indications."

Bruce Spiess, M.D., Virginia Commonwealth University Professor and Vice-Chairman of Anesthesiology, Chief of Cardiothoracic Anesthesia and Director of the Research Department of Anesthesiology, and Synthetic Blood's SAB Chairman, stated, "We plan to study the effects of repeat dosing with Oxycyte, which could provide additional clinical benefits. The time course of brain improved oxygenation occurs immediately after Oxycyte administration and lasts for approximately 18 to 24 hours. However, the potential for neuronal death can continue for as long as seven to 10 days after initial injury. Repeat dosing, if safe without any adverse side effects, could greatly increase the oxygenation of the tissue involved."

Previous animal studies have indicated that early intervention with Oxycyte helps to prevent the destruction of nerve cells in spinal cord injuries and provides oxygen to brain tissues in stroke.

Sickle cell disease is a genetic condition caused by abnormal hemoglobin that crystallizes under low oxygen concentrations. This change leads to cells becoming misshapen and unable to move through the microcirculation. Sickle cell disease currently affects an estimated 100,000 people in the United States, as many as 50 million people in the African sub-Sahara, as well as large populations in India.

Stroke is the third leading cause of death in the U.S. and accounts for more than 162,000 deaths in the U.S. each year. According to the American Heart Association, 700,000 Americans each year experience a new or recurrent stroke. Stroke is the number one cause of long-term disability among Americans.

Spinal Cord Injury is damage to the spinal cord that results in a loss of function such as mobility or feeling and can result in paralysis. Spinal cord injury affects approximately 250,000 individuals in the U.S., increasing at a rate of approximately 11,000 new cases per year.

About the Phase IIb trial

The proposed double blind, placebo-controlled Phase IIb trial is designed to compare Oxycyte with present-day advanced therapies in TBI, and is expected to enroll 100 to 150 patients at six major neurosurgery centers. The trial protocol was prepared by M. Ross Bullock, M.D., Ph.D., of the University of Miami Miller School of Medicine, Department of Neurosurgery. Dr. Bullock was a principal investigator on Synthetic Blood's Phase IIa pilot study with Oxycyte in TBI and currently serves on the Company's SAB.

About Synthetic Blood International

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.sybd.com.

[kslifka]

sybd breaking out today....slowly.  Not a ton of volume today.

[setravis]

The T/A says it.......Buy as much as you can. Bullish till death!!!
2008 is gonna be the year of SYBD. Soon a big player is gonna get them.


52wk Range: 0.07 - 0.80
Volume: 3,506,083
Avg Vol (3m): 1,197,570

Technicals
Record Price High

Last Price Quote is:
34.89%above 13-day MA
91.59%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $101.84 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[52 windsor deluxe]

man....nice...chart.....

[Houlahan]

I think a lot of times people read posts, make the trade and move on without saying anything. And that is OK. They do not have to be chatty, but sometimes I think it is nice to know people are reading and using your information. I did today and I just wanted to say "thank you". Keep posting everyone. You never know how many people are sitting in the dark watching and reading. Well, enough said. Have a great weekend everyone.

[52 windsor deluxe]

damn....your...still..around............i...hear..you........it..can..get..lonely...here..posting...when...nobody...responds..to..your...posts....but...what..the..hell...everybodys..different....

[setravis]

I think a lot of times people read posts, make the trade and move on without saying anything. And that is OK. They do not have to be chatty, but sometimes I think it is nice to know people are reading and using your information. I did today and I just wanted to say "thank you". Keep posting everyone. You never know how many people are sitting in the dark watching and reading. Well, enough said. Have a great weekend everyone.

damn....your...still..around............i...hear..you........it..can..get..lonely...here..posting...when...nobody...responds..to..your...posts....but...what..the..hell...everybodys..different....

That's what I'm talking about.......